Actively Recruiting
Improving Treatment Response in Metastatic Breast, Kidney, Ovarian, and Prostate Cancer Using Supervised Exercise and Atorvastatin A Phase III Randomized Study on Exercise and Statin Effects During Cancer Drug Treatment
Led by Tampere University Hospital · Updated on 2025-06-27
240
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether supervised physical exercise during cancer drug treatment improves treatment effectiveness in patients with metastasized breast, kidney, ovarian, and prostate cancer compared to unsupervised exercise. The study also examines if adding the cholesterol-lowering drug atorvastatin to guided group exercise further enhances responses to cancer treatment. This randomized phase III trial explores how exercise and medication may impact tumor hypoxia and lipid metabolism, which are common factors in many solid tumors that can help cancer cells survive and spread. Participants are assigned to one of three groups supervised group exercise twice a week for three months supervised group exercise combined with daily atorvastatin medication or a control group exercising independently without guidance. Additionally, a separate group of patients already using statins participates in either supervised exercise or unsupervised exercise. Physical condition and body composition are measured at the start, after three months of intervention, and again at six months. Exercise activity is tracked during follow-up visits. Participants undergo follow-up visits every three months for two years alongside their standard cancer treatment check-ups. At each visit, blood and urine samples and questionnaires are collected, and body composition and physical performance are assessed at baseline and after the intervention. Quality of life, pain, mood, nutrition, and relationships are also evaluated through interviews and questionnaires. The main outcomes measured are time to cancer progression and mortality. Other assessments include treatment tolerability, hypoxia markers, and changes in physical and mental well-being.
CONDITIONS
Brief Title
Measuring Oncological Value of Exercise and Statin
Research Team
T
Teemu Murtola, MD PhD Prof
J
Jorma Sormunen, MD PhD MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here